Antiherpesvirus activities of two novel 4'-thiothymidine derivatives, KAY-2-41 and KAH-39-149, are dependent on viral and cellular thymidine kinases

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 8, 2014, Pages 4328-4340

  Coen, Natacha ^a   Duraffour, Sophie ^a   Haraguchi, Kazuhiro ^b   Balzarini, Jan ^a   Van Den Oord, Joost J ^c   Snoeck, Robert ^a   Andreia, Graciela ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b NIHON PHARMACEUTICAL UNIVERSITY   (Japan)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

4'-THIOTHYMIDINE; ANTIVIRUS AGENT; KAH-39-149; KAY-2-41; NUCLEOSIDE; THIOPHENE DERIVATIVE; THYMIDINE; THYMIDINE KINASE; THYMIDINE KINASE 1; VIRUS PROTEIN;

3T3 CELL LINE; ANALOGS AND DERIVATIVES; ANIMAL; ANTIVIRAL RESISTANCE; DRUG EFFECTS; ENZYME ASSAY; EPSTEIN BARR VIRUS; GENETICS; GROWTH, DEVELOPMENT AND AGING; HELA CELL LINE; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HERPESVIRIDAE INFECTIONS; HOST PATHOGEN INTERACTION; HUMAN; METABOLISM; MOUSE; MUTATION; PHOSPHORYLATION; SYNTHESIS; VARICELLA ZOSTER VIRUS; VIROLOGY;

ANIMALS; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; ENZYME ASSAYS; HELA CELLS; HERPESVIRIDAE INFECTIONS; HERPESVIRUS 1, HUMAN; HERPESVIRUS 2, HUMAN; HERPESVIRUS 3, HUMAN; HERPESVIRUS 4, HUMAN; HOST-PATHOGEN INTERACTIONS; HUMANS; MICE; MUTATION; NIH 3T3 CELLS; PHOSPHORYLATION; THIONUCLEOSIDES; THIOPHENES; THYMIDINE; THYMIDINE KINASE; VIRAL PROTEINS;

EID: 84905399665     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02825-14     Document Type: Article

References (45)

1. Höcker B, Böhm S, Fickenscher H, Küsters U, Schnitzler P, Pohl M, John U, Kemper MJ, Fehrenbach H, Wigger M, Holder M, Schröder M, Feneberg R, Köpf-Shakib S, Tönshoff B. 2012. (Val-) Ganciclovir prophylaxis reduces Epstein-Barr virus primary infection in pediatric renal transplantation. Transpl. Int. 25:723-731. http://dx.doi.org/10.1111/j.1432- 2277.2012.01485.x.
2. Davis JE, Moss DJ. 2004. Treatment options for post-transplant lymphoproliferative disorder and other Epstein-Barr virus-associated malignancies. Tissue Antigen. 63:285-292. http://dx.doi.org/10.1111/j.0001-2815. 2004.00227.x.
3. Rafailidis PI, Mavros MN, Kapaskelis A, Falagas ME. 2010. Antiviral treatment for severe EBV infections in apparently immunocompetent patients. J. Clin. Virol. 49:151-157. http://dx.doi.org/10.1016/j.jcv.2010.07.008.
4. Davis CL, Harrison KL, McVicar JP, Forg PJ, Bronner MP, Marsh CL. 1995. Antiviral prophylaxis and the Epstein Barr virus-related posttransplant lymphoproliferative disorder. Clin. Transplant. 9:53-59.
5. Funch DP, Walker AM, Schneider G, Ziyadeh NJ, Pescovitz MD. 2005. Ganciclovir and acyclovir reduce the risk of post-transplant lymphoproliferative disorder in renal transplant recipients. Am. J. Transplant. 5:2894-2900. http://dx.doi.org/10.1111/j.1600-6143.2005.01115.x.
6. Malouf MA, Chhajed PN, Hopkins P, Plit M, Turner J, Glanville AR. 2002. Anti-viral prophylaxis reduces the incidence of lymphoproliferative disease in lung transplant recipients. J. Heart Lung Transplant. 21:547-554. http://dx.doi.org/10.1016/S1053-2498(01)00407-7.
7. Mentzer SJ, Perrine SP, Faller DV. 2001. Epstein-Barr virus posttransplant lymphoproliferative disease and virus-specific therapy: pharmacological re-activation of viral target genes with arginine butyrate. Transpl. Infect. Dis. 3:177-185. http://dx.doi.org/10.1034/j.1399-3062.2001. 003003177.x.
8. Kanakry JA, Ambinder RF. 2013. EBV-related lymphomas: new approaches to treatment. Curr. Treat. Options Oncol. 14:224-236. http://dx.doi.org/10.1007/ s11864-013-0231-y.
9. van Velzen M, van de Vijver DA, van Loenen FB, Osterhaus AD, Remeijer L, Verjans GM. 2013. Acyclovir prophylaxis predisposes to antiviral-resistant recurrent herpetic keratitis. J. Infect. Dis. 208:1359-1365. http://dx.doi.org/10.1093/infdis/jit350.
10. Fife KH, Crumpacker CS, Mertz GJ, Hill EL, Boone GS. 1994. Recurrence and resistance patterns of herpes simplex virus following cessation of γ or 6 years of chronic suppression with acyclovir. Acyclovir Study Group. J. Infect. Dis. 169:1338-1341. http://dx.doi.org/10.1093/infdis/169.6.1338.
11. James SH, Prichard MN. 2013. A possible pitfall in acyclovir prophylaxis for recurrent herpetic keratitis? J. Infect. Dis. 208:1353-1355. http://dx.doi.org/10.1093/infdis/jit379.
12. Burrel S, Boutolleau D, Azar G, Doan S, Deback C, Cochereau I, Agut H, Gabison EE. 2013. Phenotypic and genotypic characterization of acyclovirresistant corneal HSV-1 isolates from immunocompetent patients with recurrent herpetic keratitis. J. Clin. Virol. 58:321-324. http://dx.doi.org/10. 1016/j.jcv.2013.05.001.
13. Duan R, de Vries RD, Osterhaus AD, Remeijer L, Verjans GM. 2008. Acyclovir-resistant corneal HSV-1 isolates from patients with herpetic keratitis. J. Infect. Dis. 198:659-663. http://dx.doi.org/10.1086/590668.
14. Pan D, Kaye SB, Hopkins M, Kirwan R, Hart IJ, Coen DM. 2013. Common and new acyclovir resistant herpes simplex virus-1 mutants causing bilateral recurrent herpetic keratitis in an immunocompetent patient. J. Infect. Dis. 209:345-349. http://dx.doi.org/10.1093/infdis/jit437.
15. Dyson MR, Coe PL, Walker RT. 1991. The synthesis and antiviral activity of some 4'-thio-2'-deoxy nucleoside analogues. J. Med. Chem. 34:2782-2786. http://dx.doi.org/10.1021/jm00113a016.
16. Secrist JA, III, Tiwari KN, Riordan JM, Montgomery JA. 1991. Synthesis and biological activity of 2'-deoxy-4'-thio pyrimidine nucleosides. J. Med. Chem. 34:2361-2366. http://dx.doi.org/10.1021/jm00112a007.
17. Haraguchi K, Takahashi H, Tanaka H, Hayakawa H, Ashida N, Nitanda T, Baba M. 2004. Synthesis and antiviral activities of 1'-carbonsubstituted 4'-thiothymidines. Bioorg. Med. Chem. 12:5309-5316. http://dx.doi.org/10.1016/j. bmc.2004.07.057.
18. Prichard MN, Quenelle DC, Hartline CB, Harden EA, Jefferson G, Frederick SL, Daily SL, Whitley RJ, Tiwari KN, Maddry JA, Secrist JA, III, Kern ER. 2009. Inhibition of herpesvirus replication by 5-substituted 4'-thiopyrimidine nucleosides. Antimicrob. Agents Chemother. 53:5251-5258. http://dx.doi.org/10. 1128/AAC.00417-09.
19. Rahim SG, Trivedi N, Bogunovic-Batchelor MV, Hardy GW, Mills G, Selway JW, Snowden W, Littler E, Coe PL, Basnak I, Whale RF, Walker RT. 1996. Synthesis and anti-herpes virus activity of 2'-deoxy-4'-thiopyrimidine nucleosides. J. Med. Chem. 39:789-795. http://dx.doi.org/10.1021/jm950029r.
20. Kern ER, Prichard MN, Quenelle DC, Keith KA, Tiwari KN, Maddry JA, Secrist JA, III 2009. Activities of certain 5-substituted 4'-thiopyrimidine nucleosides against orthopoxvirus infections. Antimicrob. Agents Chemother. 53:572-579. http://dx.doi.org/10.1128/AAC.01257-08.
21. Duraffour S, Drillien R, Haraguchi K, Balzarini J, Topalis D, van den Oord JJ, Andrei G, Snoeck R. 2013. KAY-2-41, a novel nucleoside analogue inhibitor of orthopoxviruses in vitro and in vivo. Antimicrob. Agents Chemother. 58:27-37. http://dx.doi.org/10.1128/AAC.01601-13.
22. Haraguchi K, Shimada H, Tanaka H, Hamasaki T, Baba M, Gullen EA, Dutschman GE, Cheng YC. 2008. Synthesis and anti-HIV activity of 4'-substituted 4'-thiothymidines: a new entry based on nucleophilic substitution of the 4'-acetoxy group. J. Med. Chem. 51:1885-1893. http://dx.doi.org/10.1021/ jm070824s.
23. Coen N, Singh U, Vuyyuru V, Van den Oord JJ, Balzarini J, Duraffour S, Snoeck R, Cheng YC, Chu CK, Andrei G. 2013. Activity and mechanism of action of HDVD, a novel pyrimidine nucleoside derivative with high levels of selectivity and potency against gammaherpesviruses. J. Virol. 87:3839-3851. http://dx.doi.org/10.1128/JVI.03338-12.
24. Andrei G, Balzarini J, Fiten P, De Clercq E, Opdenakker G, Snoeck R. 2005. Characterization of herpes simplex virus type 1 thymidine kinase mutants selected under a single round of high-dose brivudin. J. Virol. 79:5863-5869. http://dx.doi.org/10.1128/JVI.79.9.5863-5869.2005.
25. Friedrichs C, Neyts J, Gaspar G, De Clercq E, Wutzler P. 2004. Evaluation of antiviral activity against human herpesvirus 8 (HHV-8) and Epstein-Barr virus (EBV) by a quantitative real-time PCR assay. Antiviral Res. 62:121-123. http://dx.doi.org/10.1016/j.antiviral.2003.12.005.
26. Verri A, Focher F, Duncombe RJ, Basnak I, Walker RT, Coe PL, de Clercq E, Andrei G, Snoeck R, Balzarini J, Spadari S. 2000. Anti-(herpes simplex virus) activity of 4'-thio-2'-deoxyuridines: a biochemical investigation for viral and cellular target enzymes. Biochem. J. 351(Pt 2):319-326. http://dx.doi.org/10. 1042/0264-6021:3510319.
27. Nash AA, Dutia BM, Stewart JP, Davison AJ. 2001. Natural history of murine gamma-herpesvirus infection. Philos. Trans. R. Soc. Lond. B Biol. Sci. 356:569-579. http://dx.doi.org/10.1098/rstb.2000.0779.
28. Flano E, Husain SM, Sample JT, Woodland DL, Blackman MA. 2000. Latent murine gamma-herpesvirus infection is established in activated B cells, dendritic cells, and macrophages. J. Immunol. 165:1074-1081. http://dx.doi.org/10.4049/jimmunol.165.2.1074.
29. Coen N, Duraffour S, Naesens L, Krecmerová M, Van den Oord J, Snoeck R, Andrei G. 2013. Evaluation of novel acyclic nucleoside phosphonates against human and animal gammaherpesviruses revealed an altered metabolism of cyclic prodrugs upon Epstein-Barr virus reactivation in P3HR-1 cells. J. Virol. 87:12422-12432. http://dx.doi.org/10.1128/JVI.02231-13.
30. Pérez-Pérez MJ, Hernández AI, Priego EM, Rodríguez-Barrios F, Gago F, Camarasa MJ, Balzarini J. 2005. Mitochondrial thymidine kinase inhibitors. Curr. Top. Med. Chem. 5:1205-1219. http://dx.doi.org/10.2174/156802605774463097.
31. Sasadeusz JJ, Tufaro F, Safrin S, Schubert K, Hubinette MM, Cheung PK, Sacks SL. 1997. Homopolymer mutational hot spots mediate herpes simplex virus resistance to acyclovir. J. Virol. 71:3872-3878.
32. Brown DG, Visse R, Sandhu G, Davies A, Rizkallah PJ, Melitz C, Summers WC, Sanderson MR. 1995. Crystal structures of the thymidine kinase from herpes simplex virus type-1 in complex with deoxythymidine and ganciclovir. Nat. Struct. Biol. 2:876-881. http://dx.doi.org/10.1038/nsb1095-876.
33. Graham D, Larder BA, Inglis MM. 1986. Evidence that the 'active centre' of the herpes simplex virus thymidine kinase involves an interaction between three distinct regions of the polypeptide. J. Gen. Virol. 67(Pt 4):753-758.
34. Gaudreau A, Hill E, Balfour HH, Jr, Erice A, Boivin G. 1998. Phenotypic and genotypic characterization of acyclovir-resistant herpes simplex viruses from immunocompromised patients. J. Infect. Dis. 178:297-303. http://dx.doi.org/10.1086/515626.
35. Harris W, Collins P, Fenton RJ, Snowden W, Sowa M, Darby G. 2003. Phenotypic and genotypic characterization of clinical isolates of herpes simplex virus resistant to aciclovir. J. Gen. Virol. 84:1393-1401. http://dx.doi.org/ 10.1099/vir.0.18880-0.
36. Morfin F, Souillet G, Bilger K, Ooka T, Aymard M, Thouvenot D. 2000. Genetic characterization of thymidine kinase from acyclovir-resistant and-Susceptible herpes simplex virus type 1 isolated from bone marrow transplant recipients. J. Infect. Dis. 182:290-293. http://dx.doi.org/10.1086/315696.
37. Schmit I, Boivin G. 1999. Characterization of the DNA polymerase and thymidine kinase genes of herpes simplex virus isolates from AIDS patients in whom acyclovir and foscarnet therapy sequentially failed. J. Infect. Dis. 180:487-490. http://dx.doi.org/10.1086/314900.
38. Piret J, Boivin G. 2011. Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management. Antimicrob. Agents Chemother. 55:459-472. http://dx.doi.org/10.1128/AAC.00615-10.
39. Andrei G, Topalis D, Fiten P, McGuigan C, Balzarini J, Opdenakker G, Snoeck R. 2012. In vitro-selected drug-resistant varicella-zoster virus mutants in the thymidine kinase and DNA polymerase genes yield novel phenotype-genotype associations and highlight differences between antiherpesvirus drugs. J. Virol. 86:2641-2652. http://dx.doi.org/10.1128/JVI.06620-11.
40. Frobert E, Ooka T, Cortay JC, Lina B, Thouvenot D, Morfin F. 2005. Herpes simplex virus thymidine kinase mutations associated with resistance to acyclovir: a site-directed mutagenesis study. Antimicrob. Agents Chemother. 49:1055-1059. http://dx.doi.org/10.1128/AAC.49.3.1055-1059.2005.
41. Horsburgh BC, Chen SH, Hu A, Mulamba GB, Burns WH, Coen DM. 1998. Recurrent acyclovir-resistant herpes simplex in an immunocompromised patient: can strain differences compensate for loss of thymidine kinase in pathogenesis? J. Infect. Dis. 178:618-625. http://dx.doi.org/10.1086/515375.
42. Munir KM, French DC, Dube DK, Loeb LA. 1992. Permissible amino acid substitutions within the putative nucleoside binding site of herpes simplex virus type 1 encoded thymidine kinase established by random sequence mutagenesis [corrected]. J. Biol. Chem. 267:6584-6589.
43. Wu CC, Chen MC, Chang YR, Hsu TY, Chen JY. 2004. Identification and characterization of the conserved nucleoside-binding sites in the Epstein-Barr virus thymidine kinase. Biochem. J. 379:795-803. http://dx.doi.org/10.1042/ BJ20031832.
44. Flaño E, Woodland DL, Blackman MA. 2002. A mouse model for infectious mononucleosis. Immunol. Res. 25:201-217. http://dx.doi.org/10.1385/ IR:25:3:201.
45. Tripp RA, Hamilton-Easton AM, Cardin RD, Nguyen P, Behm FG, Woodland DL, Doherty PC, Blackman MA. 1997. Pathogenesis of an infectious mononucleosis-like disease induced by a murine gammaherpesvirus: role for a viral superantigen? J. Exp. Med. 185:1641-1650. http://dx.doi.org/10.1084/jem.185.9.1641.